Prostatype Genomics

Prostate cancer is one of the most common forms of cancer and approximately 1.3 million men are diagnosed annually. Prostatype Genomics AB specializes in the development, manufacturing, and marketing of the prognostic genetic test Prostatype®. Prostatype® is a genetic test that provides a comprehensive assessment of the aggressiveness of prostate cancer.

The Prostatype prognostic gene test helps doctors and patients make correct treatment decisions for individuals with prostate cancer. By minimizing over- and under-treatment, the quality of life for patients can be improved and resources can be saved within healthcare.

Using prostate tissue from the biopsy obtained at the time of diagnosis (i.e. no new sampling of the prostate is needed), the Prostatype® test system combines gene expression information from three stem genes with currently used clinical parameters (PSA, Gleason Score, and Tumor Stage) and calculates the so-called P-score, which shows the risk of dying from prostate cancer.

Warrants of series TO6

In July 2026, Prostatype Genomics carried out a rights issue of units that raised approximately SEK 47.4 million for the Company before issue costs. Through the rights issue and a directed issue, a total of 125,225,546 warrants of series TO6 were issued. Each TO6 entitles the holder to subscribe for one (1) new share in Prostatype Genomics during the exercise period, which runs from 1 to 15 September 2026. The subscription price for TO6 has been set at SEK 0.10 per share. Upon full exercise of the warrants of series TO6, the Company will receive approximately SEK 12.5 million before issue costs. Ahead of the exercise of TO6, the Company has secured subscription commitments, letters of intent and top-down underwriting commitments totaling approximately SEK 8.7 million, corresponding to approximately 70 percent of the maximum offering volume.

Read more